The genetic marker HLA-B27 has long been linked to an increased risk of axial spondyloarthritis (axSpA), a chronic inflammatory disease primarily affecting the spine. But the precise role this gene plays in *how* the disease manifests – its clinical phenotype – remains a complex question. Latest research from a Saudi Arabian cohort suggests that HLA-B27 status does indeed influence the presentation of axSpA, particularly regarding the degree of systemic inflammation and the presence of symptoms beyond the spine, while diagnostic delays and treatment approaches appear relatively consistent across patient groups. Understanding these nuances in axial spondyloarthritis is crucial for earlier diagnosis and more tailored treatment strategies.
AxSpA encompasses conditions like ankylosing spondylitis and non-radiographic axial spondyloarthritis. Symptoms can range from chronic lower back pain and stiffness to inflammation in other joints, and even affect organs like the eyes and skin. The HLA-B27 gene, present in roughly 8% of people of European descent but varying significantly across populations, isn’t a direct cause of axSpA, but it dramatically increases susceptibility. However, not everyone with HLA-B27 develops the disease, and many with axSpA test negative for the gene. This variability highlights the need for a deeper understanding of how HLA-B27 interacts with other genetic and environmental factors to shape the disease course.
Distinct Clinical Profiles Linked to HLA-B27 Status
Researchers recently analyzed data from 84 patients in Saudi Arabia who had been diagnosed with axSpA based on MRI findings and meeting the Assessment of SpondyloArthritis International Society (ASAS) imaging criteria. The study, published in BMC Rheumatology, divided the patients into two groups: 32 who tested positive for HLA-B27 and 52 who tested negative. Alqethami A et al. (2026) found that those with the HLA-B27 gene were significantly more likely to be male, and exhibited a higher incidence of uveitis – inflammation of the middle layer of the eye – and a family history of spondyloarthritis.
Perhaps most notably, the HLA-B27 positive group demonstrated significantly elevated levels of C-reactive protein (CRP), a marker of systemic inflammation. This suggests that individuals carrying the gene may experience a more pronounced inflammatory response throughout the body, not just in the spine. This finding supports the idea that HLA-B27 positivity is associated with a more defined inflammatory phenotype, extending beyond the axial skeleton to involve extra-articular manifestations – symptoms affecting areas outside the joints.
The Role of MRI and Persistent Diagnostic Challenges
Magnetic resonance imaging (MRI) played a critical role in this study, as all participants had MRI-confirmed disease. The researchers observed a trend toward more frequent spinal inflammatory involvement on MRI in the HLA-B27 positive group, but this difference wasn’t statistically significant. Despite this, the study underscores the value of MRI in identifying axSpA, particularly in cases where the genetic marker status is unclear. Early and accurate diagnosis is often hampered by the subtle and non-specific nature of early symptoms.
A concerning finding was the substantial diagnostic delay experienced by both groups. The time between symptom onset and diagnosis remained similar regardless of HLA-B27 status. This highlights a continuing challenge in recognizing axSpA, even with the availability of advanced imaging techniques. The Spondylitis Association of America emphasizes the importance of advocating for oneself and seeking second opinions if initial diagnoses are inconclusive.
Treatment Approaches Largely Consistent
Interestingly, the use of biologic therapies – powerful medications that target specific parts of the immune system – did not differ significantly between the two groups. This suggests that treatment decisions are primarily guided by the overall disease activity and severity, rather than solely by HLA-B27 status. Peripheral manifestations, such as inflammation in other joints, were also comparable between the groups, reinforcing the complex and variable nature of axSpA.
The study authors concluded that while HLA-B27 positivity is linked to a more inflammatory and characteristic presentation of axSpA, it doesn’t appear to influence how quickly patients are diagnosed or the treatments they receive within this specific cohort. This finding is particularly relevant given the varying prevalence of HLA-B27 in different populations. In some regions, the gene is far more common than in others, potentially impacting disease presentation and diagnostic approaches.
Implications for Clinical Practice and Future Research
These findings emphasize the importance of utilizing MRI-based evaluation in the diagnosis of axSpA, especially in populations where HLA-B27 prevalence differs from that of Western countries. The study also reinforces the need for ongoing efforts to reduce diagnostic delays and improve early identification of the disease across all patient groups. Further research is needed to fully elucidate the interplay between HLA-B27, other genetic factors, and environmental triggers in the development and progression of axSpA.
The researchers suggest that a more personalized approach to axSpA management, taking into account both genetic predisposition and individual clinical characteristics, may ultimately lead to more effective treatment strategies. The next step in this research will likely involve larger, multi-center studies to validate these findings and explore the potential for targeted therapies based on HLA-B27 status and other biomarkers.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
Have you or a loved one been affected by axial spondyloarthritis? Share your experiences and thoughts in the comments below. And please, share this article with anyone who might find it helpful.
Related reading
